About: Evangelos Terpos

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evangelos Terpos Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) wetenschapper (nl) дослідник (uk) эрдэмтэн (mn) वैज्ञानिक (hi) изилдөөчү (ky) 研究者 (zh) հետազոտող (hy)
rdfs:label	Evangelos Terpos (en) Evangelos Terpos (es) Evangelos Terpos (nl) Evangelos Terpos (ast)
skos:prefLabel	Evangelos Terpos (en) Evangelos Terpos (es) Evangelos Terpos (nl) Evangelos Terpos (ast)
name	Evangelos Terpos (en) Evangelos Terpos (es) Evangelos Terpos (nl) Evangelos Terpos (ast)
instance of	wds:Q57015797-F22BE7C3-69EC-42EC-9D06-FA0A8B37BFD9
instance of	Homo sapiens
occupation	wds:Q57015797-281F6430-F10C-45F7-BCEF-0C416F3CF5F9
employer	wds:Q57015797-242675BF-026B-4021-843C-CF8087DC94FF wds:Q57015797-24ED8047-F479-445C-8FD9-9B17E93F9406 wds:Q57015797-2737F966-A4E1-462F-916F-CD094FB0DAEE wds:Q57015797-3EED3FF4-D8A0-44F1-A608-9873B2FB46F4 wds:Q57015797-60408E8B-F341-429D-BF2C-89B9718FCA0D wds:Q57015797-821DAEBC-D682-4ED2-9C21-C794EBC600AA wds:Q57015797-DADE80D8-655E-4C02-BA8D-307B219A26D8
VIAF ID	wds:Q57015797-1860E23A-9F68-4D27-9E99-D2047797EE70
GND ID	wds:Q57015797-2b6b2b1e-6ce2-47dd-8b5e-41c2dd2524a1
IdRef ID	wds:Q57015797-C216C7CC-028B-40A9-9926-7D84DCDEDABD
on focus list of Wikimedia project	wds:Q57015797-8D77096C-CE2D-4BE9-974D-0CDE06B904AA
educated at	wds:Q57015797-168A51EA-3692-42CB-84C3-CDFD274A254C wds:Q57015797-5FC19754-5D15-4695-8EDA-FDE192740A26 wds:Q57015797-7F84A5C2-D9E9-4A9A-9E77-B521DE65EDDF
PLWABN ID	wds:Q57015797-C3A13B39-DE5D-458A-98FA-9650289F758D
National Library of Israel J9U ID	wds:Q57015797-C28FA616-9AAB-46A3-A4F8-A1558A62DE09
VIAF ID	http://viaf.org/viaf/72152682588223312383
GND ID	https://d-nb.info/gnd/143650475
IdRef ID	http://www.idref.fr/225399954/id
occupation	researcher
employer	Imperial College London Hellenic Airforce General Hospital Department of Medicine of the NKUA
VIAF ID	72152682588223312383
GND ID	143650475
IdRef ID	225399954
on focus list of Wikimedia project	WikiProject COVID-19
educated at	Aristotle University of Thessaloniki Department of Medicine of the NKUA
PLWABN ID	9810608656605606
National Library of Israel J9U ID	987007407282405171
ORCID iD	wds:Q57015797-86C8DA61-B34C-4BEE-8A5F-BD272CF2E38C
ORCID iD	https://orcid.org/0000-0001-5133-1422
ORCID iD	0000-0001-5133-1422
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57015797
is author of	The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EP Sclerostin: a possible target for the management of cancer-induced bone disease Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. European Myeloma Network guidelines for the management of multiple myeloma-related complications European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years Prevention and treatment of myeloma bone disease Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group An update on the use of lenalidomide for the treatment of multiple myeloma Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH) Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study Emerging antibodies for the treatment of multiple myeloma Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies A review of the venous thrombotic issues associated with multiple myeloma Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software